Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5421]

Targeting AFP in hepatocellular cancer

Dr Lisa Butterfield University of Pittsburgh, Pittsburgh, USA

Targeting AFP in hepatocellular cancer ( Dr Lisa Butterfield University of Pittsburgh, Pittsburgh, USA )

Combination of viroimmunotherapy with checkpoint inhibitors

Prof Alan Melcher - The Institute of Cancer Research and The Royal Marsden...

Combination of viroimmunotherapy with checkpoint inhibitors ( Prof Alan Melcher - The Institute of Cancer Research and The Royal Marsden Hospital, London, UK )

Is PD-L1 really a predictive biomarker?

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

Is PD-L1 really a predictive biomarker? ( Dr Paolo Ascierto - National Tumor Institute, Naples, Italy )

Patient perspective on immunotherapy and the ITOC-3 conference

Peter Trayhurn - Patient advocate

Patient perspective on immunotherapy and the ITOC-3 conference ( Peter Trayhurn - Patient advocate )

Hypoxia and its impact on the immune system

Dr Luigi Varesio - Giannina Gaslini Institute, Genova, Italy

Hypoxia and its impact on the immune system ( Dr Luigi Varesio - Giannina Gaslini Institute, Genova, Italy )

Reprogramming the cancer microenvironment with vaccine-based therapy

Prof Lei Zheng - John Hopkins Institute Baltimore, USA

Reprogramming the cancer microenvironment with vaccine-based therapy ( Prof Lei Zheng - John Hopkins Institute Baltimore, USA )

T cells expressing two additional receptors (TETARs) for the use in a multiple...

Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany

T cells expressing two additional receptors (TETARs) for the use in a multiple- hit immunotherapy ( Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany )

Biomarkers in t-cell therapy trials

Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France

Biomarkers in t-cell therapy trials ( Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France )

Immunotherapy and personalised medicine in review

Prof Paul Sondel - University of Wisconsin, Madison, USA

Immunotherapy and personalised medicine in review ( Prof Paul Sondel - University of Wisconsin, Madison, USA )

Rationale for combining immunotherapy with chemotherapy

Prof Angus Dalgleish - St. Georges University, London UK

Rationale for combining immunotherapy with chemotherapy ( Prof Angus Dalgleish - St. Georges University, London UK )

Editor's Choice for March 2016

Prof Gordon McVie - ecancer Editor

Editor's Choice for March 2016 ( Prof Gordon McVie - ecancer Editor )

2015 ecancermedicalscience Journal Report

2015 ecancermedicalscience Journal Report ( )

More from ecancer